News Sentiment

CLGN sentiment intelligence

Collplant Biotechnologies Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.37 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+8.2% over one week, +8.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend inactive 8.5% over four weeks
Fair value -89.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 24
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 6
simplywall.st 5
DonanımHaber 4
TradingKey 4
PR Newswire 3
Quantisnow 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 23
Market update 18
Deals and strategy 3
Analyst action 3
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Stock Titan Direct company coverage

CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE

CollPlant Biotechnologies Ltd. has filed a Form F-3 prospectus to register 31,047,068 ordinary shares for resale by selling shareholders. This registration covers 4,464,707 PIPE Shares and 26,582,361 ordinary shares issuable upon exercise of warrants issued in a private placement

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

CollPlant (NASDAQ: CLGN) targets 500M authorized shares in shareholder vote

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is seeking shareholder approval to significantly increase its authorized share capital from 30 million to 500 million Ordinary Shares. This move is intended to provide the company with greater flexibility to fulfill obligations from p

Tone
Neutral 50/100
Event
Regulatory and legal
Published
08 Jul 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

CollPlant (Nasdaq: CLGN) raises $2.6M in share and warrant private deal

CollPlant Biotechnologies has secured $2.6 million through a private placement of ordinary shares and warrants. The funding will be used for general corporate purposes, including working capital, R&D, and evaluating strategic business combinations. H.C. Wainwright & Co. served as

Tone
Positive 65/100
Event
Deals and strategy
Published
01 Jul 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

CollPlant strikes $2.6M private placement, with warrants attached

CollPlant Biotechnologies has announced a definitive agreement for a $2.6 million private placement. The company will issue 7,647,061 ordinary shares (or equivalents) along with Series A and B warrants, priced at $0.34 per share and accompanying warrants. The proceeds are intende

Tone
Positive 63/100
Event
Market update
Published
30 Jun 2026 12:09
Source
Stock Titan
TradingView Direct company coverage

CollPlant Biotechnologies Ltd Actuals & Estimates (NASDAQ:CLGN)

This article provides an overview of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and upcoming earnings report. It highlights key financial figures such as recent ea

Tone
Negative 36/100
Event
Earnings
Published
25 Jun 2026 14:41
Source
TradingView
TradingKey Direct company coverage

Collplant Biotechnologies Ltd (CLGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Collplant Biotechnologies Ltd (CLGN), noting that no earnings forecast score is currently available from TradingKey. It highlights an average analyst price target of USD 11.50 for CLGN, with revenue expected to be USD 9.80M for the n

Tone
Neutral 50/100
Event
Earnings
Published
21 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

Collplant Biotechnologies Ltd (CLGN) Institutional Confidence

This article analyzes Collplant Biotechnologies Ltd (CLGN)'s institutional confidence score, which is currently 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 27.21% quarter-over-quart

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

Collplant Biotechnologies Ltd (CLGN) Financial Health: Profitability & Balance Sheet Analysis

Collplant Biotechnologies Ltd (CLGN) currently holds a financial score of 6.04, placing it 296th out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company recently reported a significant year-over-yea

Tone
Negative 28/100
Event
Market update
Published
18 Jun 2026 10:39
Source
TradingKey
Stock Titan Direct company coverage

Biotech CollPlant eyes deals after 50% staff cut and Q1 loss

CollPlant Biotechnologies reported a widened GAAP net loss of $3.1 million in Q1 2026, with revenue significantly down to $73,000 from $2.1 million in Q1 2025 due to a non-recurring milestone payment last year. The company reduced its workforce by approximately 50% and initiated

Tone
Neutral 50/100
Event
Earnings
Published
15 Jun 2026 15:10
Source
Stock Titan
Bez Kabli Direct company coverage

CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents

CollPlant (CLGN) is facing a Nasdaq deadline of September 21 to regain compliance with the $1 minimum bid price rule. The company's stock is currently trading under 40 cents, and its Q1 revenue was significantly down due to the absence of a milestone payment received the previous

Tone
Negative 29/100
Event
Earnings
Published
04 Jun 2026 04:11
Source
Bez Kabli
Finviz Direct company coverage

CLGN - CollPlant Biotechnologies Ltd Stock Price and Quote

This article provides comprehensive stock information for CollPlant Biotechnologies Ltd (CLGN), including real-time quotes, financial data, company overview, recent news, and analyst ratings. It highlights that the company's last close was at $0.3402, with key financial metrics l

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jun 2026 11:11
Source
Finviz
The Globe and Mail Direct company coverage

CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline

CollPlant Biotechnologies reported a wider net loss of $3.1 million in Q1 2026, with revenue dropping significantly to $73,000 from $2.1 million a year prior. The company is actively exploring strategic alternatives, including collaborations for its next-generation dermal fillers

Tone
Negative 29/100
Event
Earnings
Published
30 May 2026 22:09
Source
The Globe and Mail
Stock Titan Direct company coverage

CollPlant (NASDAQ: CLGN) Q1 2026 revenue plunges as losses deepen

CollPlant (NASDAQ: CLGN) reported a significant decline in Q1 2026 revenue to $73,000 from $2.055 million the previous year, primarily due to the non-recurrence of a $2.0 million milestone payment. The company's GAAP net loss widened to $3.1 million, or $0.23 per share, compared

Tone
Negative 28/100
Event
Earnings
Published
29 May 2026 20:39
Source
Stock Titan
Intellectia AI Direct company coverage

CLGN Forecast — Price Prediction for 2026. Should I Buy CLGN?

This article provides a price prediction for Collplant Biotechnologies Ltd (CLGN) stock for 2026 and beyond, based on an advanced algorithm. While short-term predictions show potential volatility and a "Strong Sell" recommendation due to negative signals and a falling trend, long

Tone
Neutral 50/100
Event
Guidance
Published
26 May 2026 02:39
Source
Intellectia AI
Quantisnow Direct company coverage

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies has released its second-quarter financial results for 2024, accompanied by a corporate update. This announcement was made via a press release distributed by Quantisnow, a platform providing real-time market data and news to retail investors. The update w

Tone
Positive 64/100
Event
Earnings
Published
23 May 2026 08:09
Source
Quantisnow